As of Sep 03
| -0.82 / -2.11%|
The 15 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 32.00, with a high estimate of 46.00 and a low estimate of 24.00. The median estimate represents a -15.79% decrease from the last price of 38.00.
The current consensus among 20 polled investment analysts is to Buy stock in Myriad Genetics Inc. This rating has held steady since September, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.